ClinicalTrials.gg
CompletedNCT03916393Updated Jun 5, 2019

PF-06651600 Taste Study.

A Phase 1 interventional study of PF-06651600 20 mg and Bitrex solution in Healthy Participants, sponsored by Pfizer. Completed at 1 site in Belgium. Open to participants aged 18 Years to 40 Years, including healthy volunteers. Per ClinicalTrials.gov, last updated 2019-06-05.

Sponsored by Pfizer · Phase 1, Interventional, and Basic science

From the registry’s dates

  • Primary completion was May 2019, 7 years 6 months ago, and no results have been posted to the registry.

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 1
Study type
Interventional
Enrollment
10
Allocation
Randomized
Ages
18 Years to 40 Years
Sex
All
01

Study summary

This is a single-blind, randomized, five (5)-period, cross-over study in healthy adult participants. A group of approximately 10 participants will assess the sensory attributes (taste and palatability) of 4 different formulations of an investigational product (PF-06651600 active pharmaceutical ingredient) and Bitrex (Registered) positive control in a specified sequence in 1 day.

02

Conditions studied

  • Healthy Participants

Keywords

  • PF-06651600
  • Palatability
  • Bitrex
  • Taste Study
03

In context

Lead sponsor

Pfizer is the lead sponsor of 3,337 studies on the registry; 150 are open to participants now.

Of its 601 completed or terminated interventional studies of FDA-regulated products, 392 (65%) have results posted.

Counted across the registry records on this site, refreshed daily.

04

Who can participate

Ages eligible
18 Years to 40 Years
Sexes eligible
All
Accepts healthy volunteers
Yes

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Willing and able to comply with all scheduled visits, treatment plan, laboratory tests, lifestyle considerations and other study procedures.
  • (BMI) of 17.5 to 30.5 kg/m2; and a total body weight >50 kg (110 lb)

Exclusion criteria

Exclusion Criteria:

  • Evidence or history of hematological, renal, endocrine, pulmonary, gastrointestinal, cardiovascular, hepatic, psychiatric, neurological, or allergic disease Infection with , C or
  • Participants with conditions that affect their ability to taste
  • Participants who currently smoke
Terms in these criteria, in plain language(4)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

BMI (body mass index)

Weight in kilograms divided by height in metres squared. Example: 70 kg and 1.75 m gives 70 ÷ (1.75 × 1.75) ≈ 22.9.

What counts as overweight or obesity differs between countries (some use lower cut-offs), so go by the range the study states.

Clinically significant

Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.

Hepatitis B tests

Hepatitis B is a virus that infects the liver. These are separate tests: HBsAg positive usually means a current infection (a recent vaccination can briefly cause it too); total anti-HBc (HBcAb) positive means an infection now or in the past; HBV DNA measures how much virus is in the blood.

Some studies accept a past infection if HBV DNA is undetectable, sometimes with antiviral medicine during the study. Check what this study allows.

HIV

The human immunodeficiency virus, which weakens the immune system.

Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.

05

Study design

Phase
Phase 1
Primary purpose
Basic science
Allocation
Randomized
Intervention model
Crossover assignment
Masking
Single (Participant)
Enrollment
10 participants (actual)

Study arms

  • Experimental
    PF-06651600 Treatment A

    Active pharmaceutical ingredient (API)solution in water

    Drug: PF-06651600 20 mg

  • Experimental
    PF-06651600 Treatment B

    API in sweetened solution

    Drug: PF-06651600 20 mg

  • Experimental
    PF-06651600 Treatment C

    API blend suspension in water

    Drug: PF-06651600 20 mg

  • Experimental
    PF-06651600 Treatment D

    API blend suspension in apple sauce

    Drug: PF-06651600 20 mg

  • Other
    Bitrex (Registered) Treatment E

    Positive control for bitterness

    Other: Bitrex solution

Interventions

  • PF-06651600 in four (4) different oral formulations will be administered in different periods.

  • OtherBitrex solution

    Bitrex solution at 0.5 ppm will be included in the treatment sequence together with the four PF-06651600 formulations.

06

What researchers measure

Primary outcomes

  1. Number of subjects reporting overall liking of drug formulation

    Overall liking assesses the degree that a participant likes a drug formulation based on sensory attributes experienced by the participant after tasting a product. It is scored based on a measurement of taste questionnaire.

    Time frame: Baseline through 20 minutes post dose

  2. Percentage of subjects reporting overall liking of drug formulation

    Overall liking assesses the degree that a participant likes a drug formulation based on sensory attributes experienced by the participant after tasting a product. It is scored based on a measurement of taste questionnaire.

    Time frame: Baseline through 20 minutes post dose

  3. Number of subjects reporting saltiness of drug formulation

    Saltiness assesses the degree that a participant experienced this sensory attribute after tasting a drug formulation. It is scored based on a measurement of taste questionnaire

    Time frame: Baseline through 20 minutes post dose

  4. Percentage of subjects reporting saltiness of drug formulation

    Saltiness assesses the degree that a participant experienced this sensory attribute after tasting a drug formulation. It is scored based on a measurement of taste questionnaire

    Time frame: Baseline through 20 minutes post dose

  5. Number of subjects reporting bitterness of drug formulation

    Bitterness assesses the degree that a participant experienced this sensory attribute after tasting a drug formulation. It is scored based on a measurement of taste questionnaire

    Time frame: Baseline through 20 minutes post dose

  6. Percentage of subjects reporting bitterness of drug formulation

    Bitterness assesses the degree that a participant experienced this sensory attribute after tasting a drug formulation. It is scored based on a measurement of taste questionnaire

    Time frame: Baseline through 20 minutes post dose

  7. Number of subjects reporting mouth feel of drug formulation

    Mouth feel assesses the degree that a participant experienced this sensory attribute after tasting a drug formulation. It is scored based on a measurement of taste questionnaire

    Time frame: Baseline through 20 minutes post dose

  8. Percentage of subjects reporting mouth feel of drug formulation

    Mouth feel assesses the degree that a participant experienced this sensory attribute after tasting a drug formulation. It is scored based on a measurement of taste questionnaire

    Time frame: Baseline through 20 minutes post dose

  9. Number of subjects reporting sourness of drug formulation

    Sourness assesses the degree that a participant experienced this sensory attribute after tasting a drug formulation. It is scored based on a measurement of taste questionnaire

    Time frame: Baseline through 20 minutes post dose

  10. Percentage of subjects reporting sourness of drug formulation

    Sourness assesses the degree that a participant experienced this sensory attribute after tasting a drug formulation. It is scored based on a measurement of taste questionnaire

    Time frame: Baseline through 20 minutes post dose

  11. Number of subjects reporting tongue/mouth burn from drug formulation

    Tongue/mouth burn assesses the degree that a participant experienced this sensory attribute after tasting a drug formulation. It is scored based on a measurement of taste questionnaire

    Time frame: Baseline through 20 minutes post dose

  12. Percentage of subjects reporting tongue/mouth burn from drug formulation

    Tongue/mouth burn assesses the degree that a participant experienced this sensory attribute after tasting a drug formulation. It is scored based on a measurement of taste questionnaire

    Time frame: Baseline through 20 minutes post dose

  13. Number of subjects reporting formulation preference

    Formulation preference assesses the degree that a participant prefers a drug formulation based on sensory attributes experienced by the participant after tasting a product. It is scored based on a measurement of taste questionnaire.

    Time frame: Baseline through 20 minutes post dose

  14. Percentage of subjects reporting formulation preference

    Formulation preference assesses the degree that a participant prefers a drug formulation based on sensory attributes experienced by the participant after tasting a product. It is scored based on a measurement of taste questionnaire.

    Time frame: Baseline through 20 minutes post dose

07

Study locations

1 site
  • Pfizer Clinical Research Unit
    Brussels, Be-bru B-1070, Belgium
08

References and documents

Individual participant data

Plan to share: No — Pfizer will provide access to individual de-identified participant data and related study documents (e.g. protocol, Statistical Analysis Plan (SAP), Clinical Study Report (CSR)) upon request from qualified researchers, and subject to certain criteria, conditions, and exceptions. Further details on Pfizer's data sharing criteria and process for requesting access can be found at: https://www.pfizer.com/science/clinical_trials/trial_data_and_results/data_requests.

09

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reached

Ran from Apr 2019 to primary completion in May 2019, 0 months.

How these figures are worked out, and which studies are left out of them.

Registered
Apr 12, 2019
First posted
Apr 16, 2019
StartActual
Apr 15, 2019
Primary completionActual
May 10, 2019
CompletionActual
May 10, 2019
Last update
Jun 5, 2019
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Jun 5, 2019, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT03916393
Lead sponsor
Pfizer
Responsible party
Sponsor
First posted
Apr 16, 2019
Start date
Apr 15, 2019
Primary completion
May 10, 2019
Completion
May 10, 2019
Last update
Jun 5, 2019

Study contacts

Pfizer CT.gov Call Center
study director · Pfizer

Oversight

Data monitoring committee
No
FDA-regulated drug
Yes
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Jun 2019. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: PF-06651600

Start the discussion